Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Oct
09
Today In Oncology
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
Predicting Future Breast Cancer Outcomes Efficacy of a Polygenic Risk Score
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia
Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo